• Protease Inhibitor Cocktail: Precision in Protein Extraction

  2026-05-06

  For researchers tackling protease-sensitive workflows, the Protease Inhibitor Cocktail (EDTA-Free, 200X in DMSO) from APExBIO delivers uncompromising protein stability during extraction, even in phosphorylation analysis or kinase assays. Its broad-spectrum, EDTA-free formulation uniquely supports advanced applications and troubleshooting in cancer signaling and resistance research.

• PP2A-Mediated Autophagy Drives Candida albicans Biofilm Drug

  2026-05-06

  This study reveals that protein phosphatase 2A (PP2A) regulates drug resistance in Candida albicans biofilms through autophagy induction, specifically via Atg13 phosphorylation and Atg1 activation. The findings highlight a mechanistic link between autophagy and decreased antifungal efficacy, providing a foundation for targeted strategies in antifungal susceptibility research.

• Low-Dose Orlistat Enhances Oxaliplatin Efficacy in Colorecta

  2026-05-05

  This study demonstrates that low-dose orlistat significantly augments the antitumor activity of oxaliplatin in colorectal cancer models through synergistic induction of apoptosis. The findings offer a promising approach to overcoming chemoresistance and improving therapeutic outcomes in metastatic colorectal cancer therapy.

• MDM1 Overexpression Sensitizes CRC to Chemoradiotherapy via

  2026-05-05

  This study identifies MDM1 as a key modulator of chemoradiotherapy sensitivity in colorectal cancer, acting through p53-mediated apoptosis pathways. The findings suggest MDM1 expression as a predictive biomarker and highlight molecular strategies to overcome resistance in CRC treatment.

• Chenodeoxycholic Acid: Optimizing FXR Pathways in Renal Rese

  2026-05-04

  Chenodeoxycholic Acid (CDCA) is redefining metabolic and renal research as a potent FXR agonist, enabling precision modeling of cholesterol metabolism and acute kidney injury pathways. This article delivers actionable protocol guidance, troubleshooting insights, and a translational bridge to the latest mechanistic findings, equipping researchers for high-impact studies in nuclear receptor signaling.

• Structure-Based Screening Identifies NSP15 Inhibitors for SA

  2026-05-04

  This study applied structure-based virtual screening and molecular dynamics to identify thymopentin and oleuropein as potent inhibitors of SARS-CoV-2 NSP15, a key endoribonuclease involved in immune evasion. Findings highlight potential new antiviral strategies targeting NSP15, offering a pipeline for rapid drug discovery in emergent viral threats.

• PEDV Exploits IMPDH Pathway: Merimepodib Blocks Viral Replic

  2026-05-03

  This study reveals how porcine epidemic diarrhea virus (PEDV) commandeers the host's IMPDH-dependent guanosine biosynthesis to drive its replication. By demonstrating that both genetic and pharmacological inhibition of IMPDH—specifically using Merimepodib (VX-497)—markedly reduces PEDV replication, the research identifies IMPDH as a promising host-directed antiviral target for veterinary coronaviruses.

• CCG-1423 (SKU B4897): Data-Driven RhoA Inhibitor for Reliabl

  2026-05-02

  CCG-1423 (SKU B4897) is a rigorously characterized small-molecule RhoA inhibitor designed for robust cell viability, proliferation, and cytotoxicity research. This article addresses real-world experimental challenges—such as reproducibility, pathway specificity, and cross-domain applications—while detailing how CCG-1423’s validated mechanisms and supplier reliability (APExBIO) provide a foundation for high-confidence results.

• Rifampin in Applied Transcriptional Regulation Workflows

  2026-05-02

  Rifampin, a rifamycin antibiotic, is indispensable for dissecting bacterial transcription and resistance mechanisms in modern molecular biology. This guide unpacks evidence-backed workflows, advanced troubleshooting, and the integration of Rifampin in optogenetic and synthetic biology research for reproducible and innovative outcomes.

• Fumagillin (SKU A4407): Reliable MetAP-2 Inhibition in Resea

  2026-05-01

  This article guides life science researchers through common challenges in cell viability and angiogenesis studies, demonstrating how Fumagillin (SKU A4407) from APExBIO provides reliable, data-backed solutions as a methionine aminopeptidase-2 inhibitor. Scenario-based Q&A blocks offer practical insights into protocol design, data interpretation, and vendor selection, helping labs achieve reproducible, sensitive results.

• Targeting β-catenin/BCL9 Interaction to Enhance Cancer Immun

  2026-04-30

  This article reviews Feng et al.'s 2019 Science Advances study, which demonstrates that pharmacological inhibition of the β-catenin/BCL9 interaction can overcome resistance to immune checkpoint inhibitors by modulating tumor-infiltrating regulatory T cells. The findings provide a mechanistic rationale for combining Wnt pathway blockade with immunotherapy in solid tumors such as colon and breast cancer.

• RSL3 and the New Frontier of Ferroptosis in Translational On

  2026-04-30

  This article explores (1S,3R)-RSL3 as a potent glutathione peroxidase 4 inhibitor, bridging mechanistic insights in ferroptosis with strategic recommendations for translational researchers. By integrating recent advances in redox biology, cross-referencing emerging clinical strategies, and evaluating experimental protocols, we highlight how RSL3 accelerates cancer research and addresses unmet needs. The discussion is grounded in up-to-date evidence, including reference to sonodynamic therapy studies and competitive landscape analyses, while providing actionable protocol guidance and a forward-looking outlook.

• UTP Solution (100 mM): Reliable RNA Synthesis & Assay Perfor

  2026-04-29

  This article explores how SKU K1048, UTP Solution (100 mM), addresses persistent challenges in RNA synthesis, cell viability, and metabolic assays. Drawing on real lab scenarios and scientific references, it demonstrates how APExBIO's high-purity uridine-5'-triphosphate trisodium salt ensures reproducibility, workflow safety, and data reliability.

• Caffeine (1,3,7-trimethylpurine-2,6-dione) in Metabolic and

  2026-04-29

  Caffeine, a rigorously characterized purine alkaloid, enables precise modulation of cellular energy pathways and robust inhibition of diverse cancer cell lines. Its performance in both in vitro and in vivo models, paired with distinct solubility and storage requirements, makes it a go-to tool for translational research in metabolic regulation and oncology.

• DNA/RNA Heteroduplex Oligonucleotides Target FGFR2 Fusion in

  2026-04-28

  This study introduces a cholesterol-conjugated DNA/RNA heteroduplex oligonucleotide (Cho-HDO) that specifically targets FGFR2 fusion mutations in intrahepatic cholangiocarcinoma (ICC). By coupling this agent with asparagine depletion, the research uncovers a new therapeutic axis to overcome resistance and improve specificity in ICC treatment.

450 records 19/30 page Previous Next First page 上5页 1617181920 下5页 Last page